anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sham control groups are essential in experimental animal studies to reduce the influence of surgical intervention. The intraluminal filament procedure is one of the most common models of middle cerebral artery occlusion (MCAO) used in the study of brain ischemia. However, a sham group is usually not included in the experimental design of these studies. In this study, we aimed to evaluate the relevance of the sham group by analyzing and comparing the brain protein profiles of the sham and MCAO groups. In the sham group, 98 dysregulated proteins were detected, compared to 171 in the ischemic group. Moreover, a comparative study of protein profiles revealed the existence of a pool of 57 proteins that appeared to be dysregulated in both sham and ischemic animals. These results indicated that the surgical procedure required for the intraluminal occlusion of the middle cerebral artery (MCA) induces changes in brain protein expression that are not associated with ischemic lesions. This study highlights the importance of including sham control groups in the experimental design, to ensure that surgical intervention does not affect the therapeutic target under study.
Purpose: The ability of low-frequency repetitive transcranial magnetic stimulation (rTMS) to enhance intracortical inhibition has motivated its use as a potential therapeutic intervention in focal hand dystonia (FHD). In this preliminary investigation, we assessed the physiologic and behavioral effects of multiple sessions of rTMS in FHD. Methods: 12 patients with FHD underwent five daily-sessions of 1 Hz rTMS to contralateral dorsal premotor cortex (dPMC). Patients held a pencil and made movements that did not elicit dystonic symptoms during rTMS. We hypothesized that an active but non-dystonic motor state would increase beneficial effects of rTMS. Five additional patients received sham-rTMS protocol. The area under curve (AUC) of the motor evoked potentials and the cortical silent period (CSP) were measured to assess changes in corticospinal excitability and intracortical inhibition, respectively. Behavioral measures included pen force and velocity during handwriting and subjective report.
FIELD: medicine, biochemistry. SUBSTANCE: invention proposes a pharmaceutical composition that can be used for inhibition of activity of 3-methyl-3-methylglutaryl-CoA-reductase in mammals. Composition has an effective amount of hesperidin or hesperetin as an active component in combination with a pharmaceutically acceptable carrier. Invention proposes also the food or drink composition designated for inhibition of activity of 3-hydroxy-3-methyl-glutaryl-CoA-reductase and containing effective amount of hesperidin and hesperetin. Composition decreases blood level cholesterol effectively. EFFECT: enhanced effectiveness of composition. 9 cl, 3 tbl, 5 ex
Disclosed are bio-active coating compositions for polymeric substrates. In particular, a bio-active coating is described which is the reaction product formed by providing a polymer backbone with at least one free isocyanate group, wherein the isocyanate group is pendant from the polymer backbone. There is further provided a hydrophilic, amine-terminated spacer which has at least one amine group at its first and second ends. One of the amine groups of the spacer is reacted with one or more of the isocyanate groups on the polymer backbone in the presence of an optional catalyst agent. A bio-active agent is then covalently bonded onto an unreacted end of the spacer in the presence of a catalyst. Also disclosed are coating compositions for a substrate and methods of preparing same.
Aging affects all cell types in the CNS and plays an important role in CNS diseases. However, the underlying molecular mechanisms driving these age-associated changes and their contribution to diseases are only poorly understood. The white matter in the aging brain as well as in diseases, such as Multiple sclerosis is characterized by subtle abnormalities in myelin sheaths and paranodes, suggesting that oligodendrocytes, the myelin-maintaining cells of the CNS, lose the capacity to preserve a proper myelin structure and potentially function in age and certain diseases. Here, we made use of directly converted oligodendrocytes (dchiOL) from young, adult and old human donors to study age-associated changes. dchiOL from all three age groups differentiated in an comparable manner into O4 + immature oligodendrocytes, but the proportion of MBP + mature dchiOL decreased with increasing donor age. This was associated with an increased ROS production and upregulation of cellular senescence markers such as CDKN1A, CDKN2A in old dchiOL. Comparison of the transcriptomic profiles of dchiOL from adult and old donors revealed 1324 differentially regulated genes with limited overlap with transcriptomic profiles of the donors' fibroblasts or published data sets from directly converted human neurons or primary rodent oligodendroglial lineage cells. Methylome analyses of dchiOL and human white matter tissue samples demonstrate that chronological and epigenetic age correlate in CNS white matter as well as in dchiOL and resulted in the identification of an age-specific epigenetic signature. Furthermore, we observed an accelerated epigenetic aging of the myelinated, normal appearing white matter of multiple sclerosis (MS) patients compared to healthy individuals. Impaired differentiation and upregulation of cellular senescence markers could be induced in young dchiOL in vitro using supernatants from pro-inflammatory microglia. In summary, our data suggest that physiological aging as well as inflammation-induced cellular senescence contribute to oligodendroglial pathology in inflammatory demyelinating diseases such as MS.
Aqueous solutions containing lipoid-soluble vitamins, suitable for parenteral administration, are produced by dissolving at least one said vitamin in a polyethylene glycol monoricinoleate containing 30-50 oxyethylene units in the molecule, and diluting the solution with water.  Lipoid-soluble vitamins A, D (calciferol) and E (a -tocopherol acetate &c.), or oleaginous glyceride-containing concentrates thereof, natural or synthetic, may be so dissolved. Water-soluble vitamins B and C may also be present.  The solutions may be clarified, if necessary, by the addition of small amounts of aliphatic or aromatic alcohols, e.g. ethanol, propanol, isopropyl alcohol, sec. butyl alcohol, propylene or butylene gycol, benzyl alcohol or mixtures thereof.
The invention discloses a radix notoginseng pharmaceutical composition for treating insomnia and a preparation method and application of the pharmaceutical composition. The pharmaceutical composition comprises the following components in parts by weight: 40-80 parts of radix notoginseng, 2-10 parts of lotus plumule, 2-10 parts of pearl powder, 1-5 parts of cinnamon, 50-150 parts of schisandra chinensis and 100-300 parts of fried spina date seeds. The method comprises the procedures of raw material preparation, extract preparation, powder preparation and mixing. Medically acceptable carriers and/or excipients are added in the pharmaceutical composition to prepare pills, ointment, sublimed preparations, tablets, capsules, oral liquid, powder and granules. The pharmaceutical composition is applied to preparation of food or medicaments for improving and/or treating insomnia. The pharmaceutical composition is reasonable in components, simple and convenient to prepare and definite in curative effect. Toxicity tests in mice and sleeping function tests show the pharmaceutical composition does not have toxic or side effect, has obvious effects of improving and treating insomnia and also has the effect of reducing blood sugar in an aided manner.
The application provides a data processing method, electronic equipment, wearable equipment and a communication system, which relate to the electronic technology and are used for monitoring physiological parameters of a user in real time, prompting the user to input relevant data in a matching way when detecting that the physiological parameters are abnormal, and carrying out relevant detection. The method is applied to the electronic equipment; the electronic device establishes a connection with the wearable device. The method comprises the following steps: in the case that the wearable device is worn on a body part of a user, a first parameter value corresponding to a preset physiological parameter acquired by the wearable device for the user is acquired based on the connection. The preset physiological parameters include at least one of: pulse wave velocity PWV, heart rate variability HRV, blood pressure, and respiratory rate. And analyzing the first parameter value to obtain a first analysis result. The first analysis result represents that the preset physiological parameters of the user are abnormal, and sends out first prompt information, wherein the first prompt information is used for prompting the user to input preset data in a matching way so as to perform new analysis on the preset physiological parameters.
<P>PROBLEM TO BE SOLVED: To provide a bactericidal deodorizer inexpensively, safely and surely carrying out bactericidal deodorization of a human body or the bactericidal deodorization of an article having a risk of oral use.  <P>SOLUTION: The bactericidal deodorizer comprises water taken from the sea and subjected to a desalination treatment and a plant extract. The water is deep sea water at ≤200 m water depth and acidified to pH≤5 by the desalination treatment. The plant extract is at least any one of extracts obtained from grains, beans, fruits, tea leaves and seaweeds. The amount of the formulated plant extract is 0.00005-0.7 wt.%. The water is obtained by diluting the balance with purified water and the dilution is ≥50 times dilution ratio.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Patients who develop recurrent hypoglycemia are predisposed to developing hypoglycemia-associated autonomic failure (HAAF, impaired awareness). There is almost no information investigating the contribution of HAAF as a risk factor for hypoglycemia in hospitalized patients. Our central aim is to develop a validated inpatient hypoglycemic symptom score model to examine HAAF and its correlation with cognitive dysfunction, re-hospitalization rates, inpatient morbidity and mortality.

This will be a prospective non-blinded study performed in a tertiary care center that will include non-critically insulin treated patients with Type 1 and 2 Diabetes. We will identify patients who have experienced moderate hypoglycemia (40-70 mg/dl) or severe hypoglycemia (\< 40 mg/dl) within the prior 24 hours by daily generated computerized reports. Participants will be asked to complete a Hypoglycemia Symptom Scores Questionnaire and cognitive testing within 24-36 hours post event. Participants will be contacted at 6 and 12 months following the index hospitalization to obtain information regarding recurrent episodes of hypoglycemia, need for re-hospitalization, and occurrence of any new diabetes related complications.
Background: Both sepsis-induced cardiomyopathy and worsening of preexisting cardiac disease can contribute to circulatory shock in septic patients. The early use of pulmonary artery catheter (PAC) could play a pivotal role in the management of sepsis-associated cardiogenic shock. In this study, we aimed to evaluate the impact of early invasive hemodynamic monitoring with PAC in patients with sepsis-associated cardiogenic shock. Method: We performed a retrospective study using the National Inpatient Sample data from January 2017 to December 2019. The early use of PAC was defined as the use of PAC within 2 days from the admission. We performed the multivariable logistic regression analysis to investigate the association between the early use of PAC and in-hospital mortality in patients with sepsis-associated cardiogenic shock and sepsis without cardiogenic shock, respectively. Results: There was no difference in in-hospital mortality between PAC and no PAC groups in sepsis without cardiogenic shock (adjusted odds ratio [aOR] = 1.05, 95% confidence interval [CI] = 0.82-1.35, P = 691). On the other hand, the early use of PAC was independently associated with lower in-hospital mortality in patients with sepsis-associated cardiogenic shock (aOR = 0.58, 95% confidence interval [CI] = 0.46-0.72, P < 0.001). The use of PAC was also associated with increased use of mechanical circulatory support in those with sepsis-associated cardiogenic shock (aOR = 12.26, 95% CI = 9.37-16.03, P < 0.001). For patients with sepsis-associated cardiogenic shock, the use of PAC after 2 days of admission was associated with significantly higher in-hospital mortality and decreased use of mechanical circulatory support. Conclusion: The use of pulmonary artery catheters in sepsis-associated cardiogenic shock was associated with significantly lower in-hospital mortality and increased use of mechanical circulatory supports in patients with sepsis-associated cardiogenic shock.
The invention relates to a functional blood sugar-reduction health product and a preparation method thereof. The functional blood sugar-reduction health product has blood sugar-reduction assistant functions and comprises hesperetin, balsam pear, American ginseng extract and wolfberry extract. The functional blood sugar-reduction health product comprises the edible and medical materials having blood sugar-reduction effects, is safe and effective and can be used for a long time. The functional blood sugar-reduction health product can be processed to form enteric coated tablets or enteric coated capsules. The preparation method comprises that the above raw materials and water and ethanol as solvents can be processed to form extract, the extract is subjected to spray drying so that extract powder is obtained, the extract powder is processed to form tablets or capsules, and the tablets or capsules are coated. An animal functional test proves that the functional blood sugar-reduction health product has blood sugar-reduction assistant health functions and is suitable for being eaten by diabetes for a long time.
Saracatinib will be administered as a once daily, oral dose of 175 mg, for a 28-day cycle, with no breaks between cycles. The duration of treatment with saracatinib will be 13 cycles.
PURPOSE:To prevent the scattering of physical properties among a large number of photopolymerization setting product from occurring and facilitate even the photopolymerization curing of the deep part of a thick-walled formed item by a method wherein visible rays are irradiated from visible ray irradiators, which are arranged at certain positions to material to be irradiated, which is continuously moved and made of visible ray polymerizable resin. CONSTITUTION:A conveyer 2 is put into operation under the condition that material to be irradiated 10 made of visible ray polymerizable resin is seated at the lead-in port 11 of material to be irradiated. The material to be irradiated 10 is continuously transferred in the controlled ambient temperature below halogen lamps 1, which irradiate visible rays so as to be carried to the carrying-out port 12 of material to be irradiated in order to complete the setting of the material to be irradiated. When the setting of a large number of materials to be irradiated is intended, the successive introduction of the materials to be irradiated in response to the transferring speed of the conveyer 2 is necessary so as to successively carry out the materials to be irradiated, which are set through the same irradiation history of visible rays and heat history as one another. Set materials or formed items, the scattering of physical properties among which is small and each of which has very stable properties, can be obtained. Even the material to be irradiated, the wall thickness of which is 10mm or more, can be easily mass-produced.
Solutions of therapeutically active water-soluble substances are prepared by extraction of bone marrow, obtained from cattle suffering from bovine cysticercosis, with water or hydroxylic organic solvents. Such solvents may be ethanol, iso-propanol, propylene glycol or glycerol, and the bone marrow may be extracted by grinding it with the solvent in the presence of an inert abrasive material such as sand.  Prior to extraction, the bone marrow is preferably defatted with a fat solvent and treated with a water-miscible ketone, e.g. acetone, and the final extract of the process is filtered, sterilised by filtration and sealed into vials.  The active substances may be employed in this form, or preferably after dilution with saline and addition of glycerol, cresol and buffering agents, as compositions for injection, and are said to have anti-tumour activity.  The substance comprises a mixture of amino acids, including one or more of leucine, iso-leucine, methionine, cystine, threonine, lysine, valine, and L-phenyl-alanine; vitamins, particularly of the B complex; serum proteins such as albumins, globulins and properdin; indole derivatives, e.g. tryptophan; enzymes, particularly proteinases; amino-aromatic compounds and purine bases; a lipopolysaccharide and iron and molybdenum derivatives.  The substance exhibits anti-folic acid activity.
PROBLEM TO BE SOLVED: To obtain the subject new compound useful for diagnosis of senile dementia, Alzheimer's disease or the like. SOLUTION: This compound is shown by formula I (X* is a radioactive halogen; R<1> and R<2> are each H, a lower alkyl, lower alkoxy, lower alkylthio, lower dialkylamino or nitro; and (n) is 0 or 1), e.g. 2,4-methano-8-iodo-9-amino1,2,3,4-tetrahydroacridine. The compound shown by formula I is obtained by reacting a compound shown by formula II (Y is a halogen or lower trialkyltin) with a radioactive metal halide (e.g. radioactive sodium or potassium iodide), preferably in the presence of an inert solvent (e.g. dimethylformamide or dimethyl sulfoxide) at 50 to 180 deg.C. The objective compound can be used to diagnose senile dementia, Alzheimer's disease or the like which are the diseases characterized by diminished acetylcholine in the brain.
PROBLEM TO BE SOLVED: To obtain a bathing agent mild to the skin, excellent in biodegradability of drain, good at environmental hygiene without adding inorganic salts such as sodium sulfate contained in a hot spring, an enzyme, an emulsifying agent, etc., by including a specific extracellular homopolysaccharide, etc. SOLUTION: This composition is obtained by formulating (A) an extracellular homopolysaccharide produced from a bacterium and (B) an amino acid (e.g. glycine) and optionally a perfume, colorant, crude medicine, an oil agent, inorganic salt, etc. An extracellular homopolysaccharide composed of β-D-glucose as a constituent saccharide is preferable as the component A. β-1,3-1,6 Glucan produced by a bacterium belonging to the genus Aureobasidium sp. is preferable as the β-D-glucose. The amount of the β-Dglucose in the bathing agent is preferably 0. 001-10 wt.% and that of the component B added is preferably 0.001-1 wt. %. The bathing agent in an amount of 20-60 mL is preferably added to about 200 liters of water in a bath.
The purpose of this clinical study is to evaluate acute effects of plant-based nutritional extracts on adult stem cells, using a randomized double-blinded placebo-controlled cross-over study design. The research involves testing of acute effects of single doses of antioxidant-rich berry-based extracts, compared to a placebo. Blood samples are taken at baseline and 1 and 2 hours after consuming a single dose. The blood will be used to measure the numbers of different types of stem cells, to evaluate potential effects of stem cell mobilization and homing after consuming plant-based extracts. Adult stem cells are a type of cells that play a role in repairing and rejuvenating various tissue and organs in the body. At NIS Labs, we have shown that many types of plant-based nutritional products have small but reproducible and significant effects on stem cells, cytokines, and regenerative growth factors.
The intervention integrates Self Help Plus (SH+) and a session for Post-Migration Living Difficulties (PMLD) for Syrian women. Participants will be randomly assigned to the SH+ combined with the PMLD session (n = 105). The participants in the experimental arm will receive SH+ combined with the PMLD session, by non-specialist facilitators.
Background: Spinal anaesthesia for caesarean delivery is often associated with hypotension. This study was conducted to evaluate the effects of rapid crystalloid (Lactated Ringer's solution) or colloid (hydroxyethyl starch; HES) cohydration with a second intravenous access line on the incidence of hypotension and ephedrine requirement during spinal anaesthesia for caesarean section.

Methods: We studied 90 women with uncomplicated pregnancies undergoing elective caesarean section under spinal anaesthesia. Intravenous access was established in all with two peripheral intravenous lines, the first being used for the baseline volume infusion. Immediately after induction of spinal anaesthesia, Lactated Ringer's solution (Group L) or HES (Group C) infusions were started at the maximal possible rate via the second line in groups L and C respectively. The third group (Group E) patients received lactated Ringer's solution at a 'keep vein open' rate to maintain the double-blind nature. The incidence of hypotension, ephedrine requirements, total amount of volume and side effects were recorded.
The mother's thyroid hormone status during gestation and the first few months after delivery can play a crucial role in maturation during the brain development of the child. Transient abnormalities in thyroid function at birth indicate developmental and cognitive disorders in adulthood. Choline supplementation during gestation and the perinatal period in rats causes long-lasting memory improvement in the offspring. However, it remains unclear whether choline is able to restore the deficits in rats with maternal hypothyroidism. The aim of this study was to evaluate the effects of choline supplementation on the alteration of cognitive-behavioral function, long-term potentiation (LTP), and morphological changes as well as apoptosis in pre-pubertal offspring rats. To induce hypothyroidism, 6-propyl-2-thiouracil was added to the drinking water from the 6th day of gestation to the 21st postnatal day (PND). Choline treatment was started twice a day on the first day of the gestation until PND 21 via gavage. LTP recording and Morris water maze (MWM) test were conducted at PND 28. Then, the rats were sacrificed to assess their brains. The results revealed that developmental thyroid hormone deficiency impaired spatial learning and memory and reduced LTP (both: P < 0.001). Choline treatment alleviated LTP (P < 0.001), as well as learning and memory deficits (P < 0.01) in both male and female hypothyroid rats. However, no significant changes were observed in the number of caspase-3 stained cells in choline-receiving hypothyroid groups. The results revealed that developmental thyroid hormone deficiency impaired spatial learning and memory and reduced LTP. Choline treatment alleviated LTP, as well as learning and memory deficits in both male and female hypothyroid rats.